EUVIMEDEUVIMED entdecken
Crossref

Designing HSP90 inhibitor drugs against mutations profiles of cancer patients

Servet Tunoglu

International Journal of Frontiers in Biology and Pharmacy Research · 2021

DOI: 10.53294/ijfbpr.2021.1.2.0045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Frontiers in Biology and Pharmacy Research, 2021. Verfasst von Servet Tunoglu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Effective drug binding to its specific receptor determines the therapeutic effect. Tumor cells employ Heat Shock Protein 90 (Hsp90) to survive as Hsp90 prevents apoptosis. The protein is the top expressed protein among others. This expression rate further increases in tumor cells and provides a fine target for drug design. However, mutations and copy number variations, single nucleotide polymorphisms of the target gene as well as strong binding of therapeutic agents to the target provide adverse effects.

Aims

This work investigates HSP90 interaction with common inhibitor geldanamycin through key mutations to understand possible effects.

Methods

In silico analysis by YASARA software was employed to reveal interactions between HSP90 WT and its mutant along with geldanamycin.

Results

One key inhibitor-resistant critical residue interaction was monitored for each cytosolic HSP90 isoform. The residues are at critical positions during conformational changes and at the mutated regions of the protein. However, finely designed geldanamycin still tolerates its binding to HSP90.

Conclusion

HSP has no introns and may seem non-mutable, but designing inhibitors by considering structural alterations increases the effectiveness of the drug candidates and limits side effects through in silico experiments.

Zitieren

APA

Tunoglu, S. (2021). Designing HSP90 inhibitor drugs against mutations profiles of cancer patients. International Journal of Frontiers in Biology and Pharmacy Research. https://doi.org/10.53294/ijfbpr.2021.1.2.0045

Vancouver

Tunoglu S. Designing HSP90 inhibitor drugs against mutations profiles of cancer patients. International Journal of Frontiers in Biology and Pharmacy Research. 2021. doi:10.53294/ijfbpr.2021.1.2.0045

BibTeX
@article{Tunoglu2021,
  author = {Tunoglu, Servet},
  title = {Designing HSP90 inhibitor drugs against mutations profiles of cancer patients},
  journal = {International Journal of Frontiers in Biology and Pharmacy Research},
  year = {2021},
  doi = {10.53294/ijfbpr.2021.1.2.0045}
}
Kostenlos starten →